Source comparison
MK-677 Protocol for Women 55+ Post-Menopause: Comparison
Men under 60 12.5–25mg daily Escalate to 25mg within 2–4 weeks 25–30mg daily Transient water retention, elevated fasting glucose (typically <10 mg/dL increase) Baseline + 12-week glucose panel Standard clinical protocols support rapid escalation with minimal m
This comparison does not assign a generated winner or score.
- Men under 60
- 12.5–25mg daily
- Escalate to 25mg within 2–4 weeks
- 25–30mg daily
- Transient water retention, elevated fasting glucose (typically <10 mg/dL increase)
- Baseline + 12-week glucose panel
- Standard clinical protocols support rapid escalation with minimal metabolic risk in this demographic
- Women 55+ postmenopause
- 10mg daily
- Hold 4 weeks per dose tier; escalate only if glucose/insulin stable
- 20mg daily (hard ceiling)
- Insulin resistance (12–18 mg/dL glucose increase common at 25mg), exacerbated sarcopenic obesity if appetite increase unmanaged
- Baseline + 4-week + 8-week + 12-week glucose, insulin, HOMA-IR, bone markers
- Slower titration with stricter glucose monitoring is non-negotiable. Bone density benefits require 12+ months, making metabolic safety the priority
- Premenopausal women
- 10–15mg daily
- Escalate to 20mg within 6–8 weeks if tolerated
- 20–25mg daily
- Moderate appetite increase, transient edema, glucose elevation (typically 5–10 mg/dL)
- Baseline + 8-week panel
- Estrogen provides partial protection against insulin resistance. Allows moderately faster escalation than postmenopausal women